MEMORANDUM
PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
FROM: Hannah Brinkley and Patrick Gallagher
TO: Linda Osei, Priya Anand
DATE: April 1, 2021
RE: Analysis of Penterra's March 8, 2021 Cease-and-Desist Letter and Vantage's March 22, 2021 Response; Evaluation of Threatened Counterclaims and Recommended Litigation Strategy
CLIENT: Penterra Pharmaceuticals Corp.
MATTER NO.: 1018-00007
This memorandum is protected by the attorney-client privilege and constitutes attorney work product. It is prepared in anticipation of litigation and is intended solely for the use of the attorneys and client representatives identified above. Any disclosure, distribution, or copying of this memorandum or its contents to unauthorized persons is strictly prohibited.
I. Purpose and Executive Summary
This memorandum analyzes the pre-filing correspondence between Penterra Pharmaceuticals Corp. ("Penterra" or "PPC") and Vantage Medical Distribution, LLC ("Vantage" or "VMD") and evaluates the viability of Vantage's threatened counterclaims in light of the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA" or the "Agreement"). The purpose of this analysis is to provide Linda and Priya with a comprehensive assessment of the legal landscape, an evaluation of the risks and vulnerabilities on both sides, and a recommended litigation strategy as Penterra prepares to initiate judicial proceedings.
The factual predicate for this memorandum arises from two principal pieces of correspondence. First, on March 8, 2021, Penterra's General Counsel, Jennifer Chao, Esq., sent a cease-and-desist letter to Donald R. Farnham, Managing Member and CEO of Vantage, demanding that Vantage immediately cease all distribution of Oncalaris® (pegvisomant-axel) in the states of New York, New Jersey, and Pennsylvania — territories that fall outside the six-state New England region defined as the exclusive "Territory" under Exhibit A to the EDA. The letter identified Vantage's tri-state activity as a material breach of Section 2.3 of the Agreement and reserved all of Penterra's rights and remedies.
Second, on March 22, 2021, Kenneth M. Rourke, lead partner at the Boston firm of Hargrove, Sinclair & Polk LLP ("HSP"), responded on behalf of Vantage. The HSP letter asserts that Vantage possesses territorial rights over the tri-state area based on (a) a January 12, 2018 email from Steven Kapoor (Penterra's VP, Commercial Operations) to Donald Farnham, which Vantage characterizes as "prior written consent" under Section 2.3, and (b) an alleged course of dealing between the parties that purportedly effected a modification to Exhibit A. The HSP letter threatens a $35 million counterclaim for breach of contract, breach of the implied covenant of good faith and fair dealing, and promissory estoppel if Penterra proceeds with appointing a competing distributor in the tri-state area.
Our summary conclusion is as follows: Penterra's cease-and-desist letter is well-founded under the plain language of the EDA. The Territory, as unambiguously defined in Exhibit A, is limited to the six New England states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. Vantage's threatened counterclaims are unlikely to succeed on the merits for three principal reasons: (1) the Kapoor Email is plainly aspirational and conditional, falling far short of the "prior written consent" contemplated by Section 2.3; (2) the written-amendment requirement in Section 13.1, which mandates a "written instrument signed by both parties," forecloses Vantage's course-of-dealing theory of implied modification; and (3) the integration clause in Section 14.8 supersedes any prior oral or written representations that Vantage might invoke. Massachusetts precedent — particularly the Supreme Judicial Court's decision in Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000) — strongly supports the enforceability of these contractual provisions.
We recommend that Penterra proceed promptly with the filing of a Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County, seeking a judicial declaration that the Territory under the EDA is limited to the six New England states and that Vantage's tri-state distribution constitutes an unauthorized breach of the Agreement. This memorandum sets forth the factual background, legal analysis, and strategic considerations underlying that recommendation.
II. Background Facts
A. The Parties
1. Penterra Pharmaceuticals Corp.
Penterra Pharmaceuticals Corp. is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PTRA. The company maintains its principal headquarters at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra is a mid-cap specialty pharmaceutical company with a commercial focus in three therapeutic areas: oncology, rare diseases, and immunology. For fiscal year 2021, Penterra reported consolidated revenue of approximately $1.87 billion. Its flagship oncology product, Oncalaris® (pegvisomant-axel) — the product at the center of this dispute — accounted for approximately $412 million in revenue, representing roughly 22% of total consolidated revenue. Oncalaris® is a critical growth driver for the company and is the subject of ongoing commercial expansion efforts, including the Meridian arrangement discussed below.
The following individuals at Penterra are relevant to this dispute:
• Dr. Marcus Lindholm — Chief Executive Officer. Dr. Lindholm executed the EDA on Penterra's behalf in his capacity as CEO.
• Jennifer Chao, Esq. — General Counsel. Ms. Chao authored the March 8, 2021 cease-and-desist letter and serves as our primary point of contact.
• Steven Kapoor — Vice President, Commercial Operations. Mr. Kapoor is the author of the January 12, 2018 email that is central to Vantage's claims, and he was the principal Penterra relationship manager for the Vantage account.
• Rachel Mendez — Director of Distribution & Logistics. Ms. Mendez oversees distribution data reporting and was among the first Penterra personnel to identify anomalies in Vantage's shipping patterns.
2. Vantage Medical Distribution, LLC
Vantage Medical Distribution, LLC is a limited liability company organized under the laws of the Commonwealth of Massachusetts. Its principal office is located at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage is a regional specialty pharmaceutical distributor founded in 2009 by Donald R. Farnham. The company focuses on distributing branded specialty pharmaceutical products to hospitals, oncology clinics, and specialty pharmacy outlets throughout the northeastern United States. For fiscal year 2021, Vantage reported total revenue of approximately $148 million, of which approximately $67 million — roughly 45.3% — was derived from the distribution of Penterra products, primarily Oncalaris® and Renuvesta®. This significant revenue dependency on the Penterra relationship is a key strategic factor in evaluating Vantage's posture and settlement incentives.
The following individuals at Vantage are relevant to this dispute:
• Donald R. Farnham — Managing Member and Chief Executive Officer. Mr. Farnham is the founder and controlling principal of Vantage and the recipient of the March 8, 2021 cease-and-desist letter.
• Lisa Petrangelo — Chief Operating Officer. Ms. Petrangelo oversees day-to-day operations and logistics.
• Brian Kopec — Outside Sales Director. Mr. Kopec is believed to have directed and coordinated Vantage's sales expansion into the tri-state area.
Vantage has retained the Boston office of Hargrove, Sinclair & Polk LLP, with Kenneth M. Rourke serving as lead partner, to represent it in this matter.
B. The Exclusive Distribution Agreement
The Exclusive Distribution Agreement between Penterra and Vantage has an effective date of July 1, 2017. The Agreement provides for an initial term of five years, expiring on June 30, 2022, with two successive one-year automatic renewal options. Auto-renewal is subject to either party's right to give 180 days' prior written notice of non-renewal, meaning that notice of non-renewal for the first renewal period must be provided by approximately January 1, 2022.
The EDA covers two Penterra products: (a) Oncalaris® (pegvisomant-axel), available in 20 mg and 40 mg vial configurations, and (b) Renuvesta® (cilosporin-beta), available in 5 mg capsule form. Oncalaris® is by far the more commercially significant product and is the product at issue in this dispute.
The following provisions of the EDA are directly relevant to the present controversy:
Section 2.1 — Grant of Exclusive Territory. This section provides: "Supplier hereby grants to Distributor the exclusive right to distribute the Products within the Territory, as defined in Exhibit A." The grant is explicitly tied to, and limited by, the definition of "Territory" set forth in Exhibit A.
Exhibit A — Territory Definition. Exhibit A states in full: "The states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont (collectively, the 'New England States')." The definition is precise and enumerative. It names six states. It does not include New York, New Jersey, or Pennsylvania. It contains no catch-all language, no reference to "surrounding" or "adjacent" states, and no provision for future territorial expansion. The geographic scope of the Agreement is, on its face, unambiguous.
Section 2.3 — Limitation. This section provides: "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." This provision establishes a clear prohibition on out-of-territory activity and makes any expansion conditional on Penterra's affirmative, written authorization. The phrase "prior written consent" implies a deliberate, specific authorization — not a general expression of interest or willingness to discuss future possibilities.
Section 5.2 — Minimum Annual Purchase Commitment. This section establishes a minimum annual purchase commitment for Oncalaris® of $9.5 million per year at wholesale acquisition cost (WAC). As discussed below, Vantage has exceeded this minimum in every year of the Agreement's term.
Section 13.1 — Amendments. This section provides: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." This is a standard anti-oral-modification clause, and its enforceability under Massachusetts law is well established. The provision requires dual-signature written instruments — not emails, not oral representations, and not course-of-dealing conduct.
Section 14.2 — Governing Law. The Agreement is governed by the laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.
Section 14.5 — Dispute Resolution. The parties have consented to the exclusive jurisdiction of the state or federal courts located in the Commonwealth of Massachusetts for the resolution of any dispute arising under or in connection with the Agreement.
Section 14.8 — Entire Agreement / Integration Clause. This section provides: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a standard integration clause that bars the introduction of extrinsic evidence to vary or supplement the terms of the Agreement. It reinforces the primacy of the written text, including the territorial definition in Exhibit A.
Copies of the relevant EDA provisions are attached as Appendix C.
C. Vantage's Performance History
Vantage's purchase history under the EDA demonstrates consistent over-performance relative to the $9.5 million annual minimum purchase commitment for Oncalaris® at WAC. The relevant data, based on Penterra's internal sales records, is as follows:
As the table illustrates, Vantage's purchase volumes have grown substantially each year, nearly doubling from FY 2018 to the annualized FY 2021 figure. This growth trajectory is notable for two reasons. First, it reflects Vantage's strong commercial execution within New England, which has been beneficial to Penterra. Second, and more relevant to this dispute, Vantage will almost certainly cite this growth as circumstantial evidence that the parties contemplated an expanding relationship, including eventual territorial expansion into the tri-state area. While this narrative has surface-level appeal, it does not alter the legal analysis: purchase volume growth within the defined Territory does not, standing alone, constitute evidence of an agreement to expand the Territory, particularly in the face of the written-amendment clause and integration clause.
We also note that the dramatic uptick in Vantage's FY 2021 purchases (annualized at approximately $21.47 million) may be partially attributable to revenues generated by Vantage's unauthorized tri-state distribution activities, which commenced in approximately September 2020. We should investigate this point further during discovery.
D. Vantage's Unauthorized Tri-State Activity
On or about September 14, 2020, Vantage began shipping Oncalaris® to hospitals and oncology clinics located in the states of New York, New Jersey, and Pennsylvania — none of which are within the Territory as defined in Exhibit A. Based on information available from Penterra's internal distribution reports and from assertions contained in the HSP letter, Vantage's reported tri-state revenues for the period from approximately September 2020 through March 2021 totaled approximately $6.4 million.
Penterra became aware of the tri-state activity through two channels: (1) internal distribution and sales reports maintained by Rachel Mendez's team in the Distribution & Logistics department, which reflected shipment destinations outside New England, and (2) customer inquiries from hospitals and oncology clinics in New York and New Jersey that had begun receiving Oncalaris® shipments from Vantage and had questions about the supply chain arrangement. The precise date on which Penterra personnel first became aware of the tri-state shipments is a factual question that requires further investigation and is discussed in Section V.A below.
We note that the HSP letter also references Vantage's "shipments to New York beginning in late 2019," which predates the September 14, 2020 commencement date reflected in Penterra's records. If there were earlier, smaller-scale shipments to New York in late 2019, this would extend the timeline of unauthorized activity and could potentially be used by Vantage to argue a longer period of acquiescence. We address this issue in Section V.A below and recommend immediate investigation.
E. The Kapoor Email (January 12, 2018)
A single email, sent by Steven Kapoor to Donald Farnham on January 12, 2018, is the centerpiece of Vantage's legal position. The email reads in full:
"Don — good catching up yesterday. We're definitely open to exploring expansion into NY/NJ/PA once your New England footprint is fully ramped. Let's circle back mid-year and see where things stand."
The parties assign diametrically opposed significance to this email. Vantage's position, as articulated in the HSP letter, is that the Kapoor Email constituted "prior written consent" under Section 2.3 of the EDA, or, in the alternative, that it effected an amendment or modification to Exhibit A by expanding the Territory to include New York, New Jersey, and Pennsylvania. Penterra's position — which we believe is correct — is that the email expressed nothing more than a willingness to explore future negotiations regarding a potential territorial expansion. The email is replete with conditional and aspirational language: "open to exploring" Signals a willingness to discuss, not a grant of authorization; "once your New England footprint is fully ramped" imposes a precondition that the email itself acknowledges had not yet been satisfied; and "let's circle back mid-year and see where things stand" defers any further discussion to a future date.
No subsequent written instrument was ever executed by the parties expanding the Territory. No formal follow-up meeting or negotiation session regarding tri-state expansion has been identified in the record to date, although this is a point requiring further investigation with Steven Kapoor.
A copy of the Kapoor Email is attached as Appendix D.
F. The Meridian Term Sheet
On February 15, 2021, Penterra executed a term sheet with Meridian National Distributors, Inc. ("Meridian"), a New York corporation with its principal office at 520 Seventh Avenue, 12th Floor, New York, New York 10018. Meridian is led by its President, Thomas Welliver. The term sheet contemplates a distribution arrangement under which Meridian would distribute Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland.
The Meridian arrangement represents a significant commercial opportunity for Penterra, as it would establish a dedicated distribution channel in the densely populated tri-state corridor and the adjacent Maryland market. However, the Meridian deal has stalled since Vantage asserted its purported exclusive rights over the tri-state area. Meridian has expressed reluctance to proceed until the territorial dispute with Vantage is resolved, and Penterra has indicated to Meridian that it intends to seek judicial resolution. A favorable declaratory judgment clearing the tri-state area of Vantage's claims would enable Penterra to finalize the Meridian arrangement and proceed with its commercial expansion strategy.
III. Analysis of Penterra's March 8, 2021 Cease-and-Desist Letter
A. Summary of the Letter's Content
The cease-and-desist letter, dated March 8, 2021, was authored by Jennifer Chao, Penterra's General Counsel, and addressed to Donald R. Farnham in his capacity as Managing Member and CEO of Vantage Medical Distribution, LLC. A copy of the letter is attached as Appendix A.
The letter contains the following substantive elements:
1. Identification of the Contractual Violation. The letter identifies Vantage's distribution of Oncalaris® in the states of New York, New Jersey, and Pennsylvania as a violation of Section 2.3 of the EDA, which prohibits the Distributor from actively soliciting orders for, or delivering, the Products outside the Territory without Supplier's prior written consent.
2. Demand for Cessation. The letter demands that Vantage immediately cease all distribution, solicitation, and delivery of Oncalaris® outside the six New England states defined in Exhibit A to the EDA.
3. Compliance Deadline. The letter sets a deadline of March 22, 2021 — fourteen days from the date of the letter — for Vantage to confirm in writing that it has ceased all tri-state distribution activities and that no further shipments outside the Territory will occur.
4. Reservation of Rights. The letter expressly reserves all of Penterra's rights and remedies under the Agreement and at law, including, without limitation, the right to seek damages, injunctive relief, termination of the Agreement, or any other relief to which Penterra may be entitled.
B. Assessment of the Letter's Legal Sufficiency
The cease-and-desist letter is a well-drafted instrument that serves its intended purpose effectively. We offer the following assessment:
Accurate identification of controlling provisions. The letter correctly identifies Sections 2.1 and 2.3 of the EDA, as well as Exhibit A, as the provisions governing the scope of Vantage's territorial rights and the prohibition on out-of-territory distribution. This precision is important because it anchors Penterra's position in the unambiguous text of the Agreement and signals to Vantage (and to HSP) that Penterra intends to rely on the plain language of the contract.
Formal notice of breach. The letter serves as Penterra's formal, written notification to Vantage that Penterra considers the tri-state distribution activity to be a material breach of the EDA. This notice is significant for several reasons. First, it establishes a clear record that Penterra did not consent to, acquiesce in, or waive its right to object to Vantage's out-of-territory activity. Second, it negates any future argument by Vantage that Penterra's silence or inaction after the letter constituted an implied waiver of its contractual rights. Third, in the event that Penterra subsequently elects to terminate the EDA for cause, the letter may serve as the required notice of breach under any applicable cure provisions.
Reservation of rights. The letter's reservation-of-rights language is broad and appropriately drafted. It preserves Penterra's ability to pursue any available remedy, including damages (both compensatory and consequential), injunctive relief (both preliminary and permanent), termination of the Agreement, and declaratory judgment. This flexibility is essential, as it allows Penterra to select its litigation strategy without concern that the cease-and-desist letter may have inadvertently limited its options.
Deliberate omission of the Kapoor Email. We note that the letter does not reference the January 12, 2018 Kapoor Email. Based on our discussions with Jennifer Chao, this was a deliberate strategic choice designed to avoid dignifying Vantage's anticipated reliance on the email and to prevent Penterra from inadvertently characterizing the email in a manner that might be used against it. We concur with this approach at the pre-filing stage; however, we should be fully prepared to address the Kapoor Email squarely and aggressively in our complaint, in summary judgment briefing, and, if necessary, at trial. Ignoring the email in litigation would be counterproductive — it must be confronted and contextualized.
C. Potential Weaknesses
While the cease-and-desist letter is legally sound, we identify the following areas of potential vulnerability that Vantage may seek to exploit:
Timing of the objection. The most significant factual vulnerability is the approximately six-month gap between Vantage's commencement of tri-state shipments (on or about September 14, 2020) and the date of the cease-and-desist letter (March 8, 2021). This delay — approximately 175 days — provides Vantage with a factual basis to argue that Penterra was aware of the tri-state activity and chose not to object, thereby implicitly consenting to or acquiescing in the expanded distribution. While this argument faces formidable contractual obstacles (discussed in Section IV.B.2 below), the factual optics of the delay are unfavorable and will require careful management.
Penterra's internal awareness. Closely related to the timing issue is the question of when specific Penterra personnel first became aware of Vantage's tri-state shipments and what, if any, internal communications discussed the issue before the cease-and-desist letter was sent. Rachel Mendez, as Director of Distribution & Logistics, is the individual most likely to have had early visibility into the shipping data. Steven Kapoor, as the relationship manager for the Vantage account, may also have been aware. If internal emails or memoranda show that Penterra personnel were aware of the tri-state activity months before the cease-and-desist letter and chose not to act, Vantage will argue that this pattern constitutes knowing acquiescence.
Recommended mitigation. We recommend that Jennifer Chao conduct an immediate internal review to establish a precise timeline of Penterra's awareness of the tri-state activity. This review should encompass distribution reports, internal emails, and any memoranda or meeting notes referencing Vantage's out-of-territory shipments. The results of this review should be documented and provided to us so that we can develop a factual narrative that explains the delay (e.g., internal investigation, desire to address the matter through business channels before escalating to legal action, etc.) and prepare for cross-examination on this topic.
IV. Analysis of Vantage's March 22, 2021 Response Letter
A. Summary of the HSP Letter's Content
On March 22, 2021 — the same day as the compliance deadline set by Penterra's cease-and-desist letter — Kenneth M. Rourke, lead partner at Hargrove, Sinclair & Polk LLP (200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109), sent a seven-page letter to Jennifer Chao on behalf of Vantage. A copy of the HSP letter is attached as Appendix B. The letter's principal arguments and demands are as follows:
Assertion of tri-state territorial rights. The HSP letter asserts that Vantage possesses the right to distribute Oncalaris® in New York, New Jersey, and Pennsylvania based on two legal theories:
First, the letter contends that the January 12, 2018 Kapoor Email constituted "prior written consent" within the meaning of Section 2.3 of the EDA, thereby authorizing Vantage to distribute the Products in the tri-state area. The letter characterizes the email as a written communication from a senior Penterra executive that expressly contemplated expansion into New York, New Jersey, and Pennsylvania, and argues that Vantage reasonably relied on this communication in making substantial investments in tri-state distribution infrastructure.
Second, the letter contends that Penterra's course of dealing over a three-year period — including its alleged failure to object to Vantage's shipments to New York beginning in late 2019 and its failure to object to the broader tri-state expansion for approximately six months — effected a modification of Exhibit A to include the tri-state states within the Territory. The letter argues that Penterra's pattern of silence and acquiescence was inconsistent with its contractual right to restrict Vantage's distribution footprint and that Penterra is now estopped from enforcing the original territorial limitation.
Threatened $35 million counterclaim. The HSP letter threatens that if Penterra proceeds with appointing a competing distributor (i.e., Meridian) in the tri-state area, Vantage will file a counterclaim seeking not less than $35 million in damages on three grounds: (a) breach of contract, (b) breach of the implied covenant of good faith and fair dealing, and (c) promissory estoppel. The letter does not provide a detailed breakdown or methodology for the $35 million figure.
Demand for withdrawal. The letter demands that Penterra withdraw the cease-and-desist letter and confirm in writing that Vantage's exclusive distribution rights extend to the tri-state area.
B. Assessment of Vantage's Legal Theories
1. Kapoor Email as "Prior Written Consent" (Section 2.3)
Vantage's primary legal theory is that the January 12, 2018 Kapoor Email constitutes the "prior written consent" required by Section 2.3 of the EDA for distribution outside the Territory. This argument is, in our assessment, weak and unlikely to succeed under Massachusetts contract interpretation principles.
The email's language is plainly forward-looking and conditional. The Kapoor Email contains three operative phrases, each of which signals a future-oriented, contingent intention rather than a present grant of authority:
• "We're definitely open to exploring expansion into NY/NJ/PA" — The phrase "open to exploring" is an expression of willingness to consider a future possibility, not a grant of permission. "Exploring" connotes investigation, discussion, and negotiation — processes that may or may not result in an agreement. A reasonable reader would not interpret "open to exploring" as equivalent to "we hereby consent to" or "you are authorized to proceed with."
• "once your New England footprint is fully ramped" — This subordinate clause imposes an express precondition: the expansion discussion is contingent on Vantage first fully developing its existing New England business. As of January 2018, Vantage was only six months into the EDA's term and had yet to demonstrate the sustained performance that would satisfy this condition. The use of "once" — a temporal conjunction indicating a future event — further confirms the prospective nature of the communication.
• "Let's circle back mid-year and see where things stand" — This closing phrase defers the conversation to a future date. It does not commit either party to any course of action and expressly contemplates that the situation will be reassessed at a later time. The phrase "see where things stand" underscores the open-ended, evaluative nature of the inquiry.
Massachusetts contract interpretation principles confirm the non-consent character of the email. Under Massachusetts law, the interpretation of contract terms is a question of law for the court where the language is clear and unambiguous. Bank v. Thermo Elemental Inc., 451 Mass. 638, 648 (2008). The objective test for contract interpretation asks how a reasonable person in the position of the parties would have understood the communication. Freelander v. G. & K. Realty Corp., 357 Mass. 512, 516 (1970). Applying this standard, a reasonable person receiving the Kapoor Email would understand it as a general expression of interest in future discussions, not as a present authorization to commence distribution in New York, New Jersey, and Pennsylvania. The hedged, conditional, and aspirational language is wholly inconsistent with the type of deliberate, affirmative authorization that the phrase "prior written consent" in Section 2.3 implies.
Authority question. We note as a secondary consideration that the Kapoor Email was sent by Steven Kapoor in his capacity as Vice President, Commercial Operations. The EDA itself was executed by Dr. Marcus Lindholm as CEO. To the extent Vantage argues that the email constitutes "consent" under Section 2.3, a threshold question arises as to whether Mr. Kapoor possessed the authority to grant territorial consent on behalf of Penterra. While we believe this argument is secondary — because the email does not constitute consent regardless of the author's authority — it provides an additional basis for challenging Vantage's theory. We should confirm with Jennifer Chao whether any internal delegations of authority would bear on this question and whether Penterra's corporate governance documents restrict the ability to modify distribution agreements to officers at the C-suite level.
Assessment: Vantage's argument that the Kapoor Email constitutes "prior written consent" under Section 2.3 is weak. The email does not constitute consent on its face, and its conditional language renders it legally insufficient to satisfy the contractual requirement. We assign a low probability of success to this theory.
2. Course of Dealing / Implied Modification
Vantage's secondary legal theory is that Penterra's failure to object to Vantage's out-of-territory shipments over an extended period effected an implied modification of Exhibit A, expanding the Territory to include New York, New Jersey, and Pennsylvania. This theory faces formidable contractual and doctrinal obstacles under Massachusetts law.
Written-amendment clause (Section 13.1). The EDA contains an unambiguous anti-oral-modification provision requiring that any amendment, modification, or waiver be set forth in a "written instrument signed by both parties." No such signed amendment exists. Vantage does not contend — and cannot contend — that the parties ever executed a written instrument amending Exhibit A to add the tri-state states to the Territory definition. The Kapoor Email, even if it could be characterized as some form of written communication regarding territorial expansion (which, as discussed above, it cannot), was not "signed by both parties" and therefore does not satisfy Section 13.1.
Integration clause (Section 14.8). The EDA's integration clause provides that the Agreement, including all Exhibits, constitutes the "entire agreement" between the parties and "supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This clause reinforces the exclusivity of the written contract as the source of the parties' rights and obligations. It expressly bars reliance on prior negotiations or representations — including the Kapoor Email, which predates the alleged tri-state activity by over two years — to vary or supplement the terms of the Agreement.
Massachusetts law on anti-oral-modification clauses. Under Massachusetts law, written-modification clauses are generally enforceable and are not treated as mere formalities that can be overridden by course of dealing or verbal agreements. The Supreme Judicial Court's decision in Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), is directly on point. In Cambridge Biotech, the SJC held that anti-oral-modification provisions serve an important commercial function by ensuring that modifications to complex agreements are deliberate and documented. The court rejected the argument that a course-of-dealing could override an express written-modification requirement, emphasizing that parties who include such provisions in their agreements are entitled to rely on them. The rationale underlying this holding applies with full force here: Sections 13.1 and 14.8 were negotiated provisions that the parties included in the EDA to ensure that any changes to the Agreement's terms — including, critically, the territorial scope — would be the product of deliberate, bilateral, written action, not unilateral assumption or informal course of dealing.
Silence as assent. Vantage argues that Penterra's failure to object to tri-state shipments over a period of approximately six months (and possibly longer, if the late-2019 New York shipments referenced in the HSP letter are confirmed) constitutes acceptance of or acquiescence in the territorial expansion. Under Massachusetts law, however, mere inaction does not ordinarily constitute assent to a contract modification. See Loranger Constr. Corp. v. E.F. Hauserman Co., 376 Mass. 757, 761 (1978) (silence does not constitute acceptance unless the offeree has a duty to speak). This principle is especially strong where the contract itself requires written amendments: a party's silence in the face of the other party's unilateral action cannot satisfy a contractual requirement for a signed written instrument. To hold otherwise would render Section 13.1 a nullity — a result that Massachusetts courts are not inclined to reach.
The six-month delay. We acknowledge that the approximately six-month delay between the commencement of tri-state shipments and the cease-and-desist letter is a factual vulnerability. Vantage's counsel will likely argue that the delay demonstrates that Penterra was content with the arrangement and only objected when the Meridian opportunity arose. However, the contractual provisions provide a strong shield: even if Penterra was aware of the tri-state activity and chose not to object immediately, the written-amendment clause prevents that silence from being construed as a modification of the Agreement. Moreover, the cease-and-desist letter itself, once sent, constitutes an unambiguous repudiation of any implied consent, and Penterra's reservation of rights preserves its ability to seek remedies for the entire period of unauthorized activity.
Assessment: Vantage's course-of-dealing argument is legally insufficient given the written-amendment clause (Section 13.1), the integration clause (Section 14.8), and the controlling Massachusetts precedent in Cambridge Biotech. While the six-month delay creates unfavorable optics, the contractual framework strongly favors Penterra. We assign a low probability of success to this theory.
3. Assessment of the $35 Million Counterclaim Threat
The HSP letter threatens a $35 million counterclaim but does not provide a breakdown of the figure or a methodology for its calculation. Based on our preliminary analysis, the $35 million likely encompasses some combination of: (a) lost future profits from tri-state distribution (projected over the remaining term of the EDA and potential renewal periods), (b) loss of Vantage's investment in tri-state infrastructure and customer relationships, and (c) reliance damages arising from Vantage's expenditures in developing the tri-state market. We analyze each of the three threatened counterclaims below.
(a) Breach of Contract. To prevail on a breach-of-contract counterclaim, Vantage would need to prove that Penterra breached an obligation owed to Vantage under the EDA. The threshold question is whether the Territory encompasses the tri-state states. If — as the plain language of Exhibit A provides — the Territory is limited to the six New England states, then Penterra owed no obligation to Vantage with respect to the tri-state area. Under this interpretation, Penterra's appointment of a competing distributor in New York, New Jersey, and Pennsylvania cannot constitute a breach, because Vantage had no contractual right to exclusivity in those states.
This counterclaim is essentially the mirror image of the declaratory-judgment question. If Penterra prevails on the territory interpretation — as we believe it will — the breach-of-contract counterclaim necessarily fails as a matter of law. The claim rises or falls with Vantage's ability to demonstrate that the Territory was expanded beyond the six New England states, either through the Kapoor Email (Section 2.3 consent) or through course of dealing (implied modification). For the reasons discussed above, both theories are legally deficient.
Assessment: Low risk if the court accepts the plain language of Exhibit A, which we believe it will.
(b) Breach of Implied Covenant of Good Faith and Fair Dealing. Under Massachusetts law, every contract contains an implied covenant of good faith and fair dealing. Fortune v. National Cash Register Co., 373 Mass. 96, 104 (1977). However, the covenant is limited in scope and cannot be invoked to override express contract terms or to create substantive rights that the parties did not agree to. Vireo & Co. v. Boston Kenmore Realty Corp., 441 Mass. 376, 385 (2004). The covenant protects a party's right to receive the fruits of the agreement as made, but it does not expand those fruits beyond what the agreement provides.
Vantage would need to demonstrate that Penterra acted in bad faith to deprive Vantage of the benefit of its bargain under the EDA. The "benefit of the bargain" that Vantage received was the exclusive right to distribute Oncalaris® and Renuvesta® within the six New England states — a right that Penterra has never challenged, threatened, or diminished. Penterra's decision to appoint a different distributor in states that are outside Vantage's Territory is not an act of bad faith; it is the exercise of a right that Penterra retained under the Agreement. The implied covenant does not extend the Territory beyond what Exhibit A expressly provides.
Vantage may attempt to reframe this claim by arguing that Penterra's "true motivation" for enforcing the territorial restriction is to replace Vantage with a more favorable distributor, and that this constitutes bad faith given the parties' long-standing relationship and Vantage's strong performance. While this narrative may have emotional resonance, it is legally insufficient. A party does not act in bad faith by enforcing the express terms of its contract. See Eigerman v. Putnam Invs., Inc., 450 Mass. 121, 129 (2007) (the implied covenant cannot be used "to create rights and duties not otherwise provided for in the contractual relationship").
Assessment: Low risk. The standard doctrinal limitations on the implied covenant of good faith and fair dealing strongly favor Penterra. This counterclaim adds little independent risk beyond the breach-of-contract theory.
(c) Promissory Estoppel. To establish a claim for promissory estoppel under Massachusetts law, Vantage must prove three elements: (1) a clear and unambiguous promise, (2) reasonable and foreseeable reliance by the promisee, and (3) the promisee actually relied on the promise to its detriment. Loranger Constr. Corp. v. E.F. Hauserman Co., 376 Mass. 757, 761 (1978); Cellucci v. Sun Oil Co., 2 Mass. App. Ct. 722, 728 (1974).
Vantage would point to the Kapoor Email as the operative "promise" supporting its estoppel claim. This theory encounters several significant problems:
No clear and unambiguous promise. The Kapoor Email is neither clear nor unambiguous. As discussed extensively above, the email is hedged with conditional and aspirational language ("open to exploring," "once your New England footprint is fully ramped," "let's circle back"). Under Massachusetts law, a statement that is tentative, conditional, or subject to future discussion does not qualify as a "clear and unambiguous promise" for purposes of promissory estoppel. See Rhode Island Hosp. Trust Nat'l Bank v. Varadian, 419 Mass. 841, 850 (1995) (promissory estoppel requires "an unambiguous promise on which the promisee could reasonably be expected to rely").
Promissory estoppel cannot override an integrated contract. Massachusetts courts are reluctant to apply promissory estoppel to contradict the express terms of a fully integrated written agreement. See Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court, 448 Mass. 15, 28-29 (2006). The EDA contains both an integration clause (Section 14.8) and a written-amendment clause (Section 13.1). Permitting Vantage to invoke promissory estoppel based on the Kapoor Email would effectively allow an informal, unilateral email to override the bargained-for territorial limitations and procedural safeguards of a fully integrated commercial agreement. Courts are justifiably wary of such an outcome, as it would undermine the certainty and predictability that integration and written-amendment clauses are designed to provide.
Reliance damages are likely limited. Even if Vantage could establish the first two elements — which we do not believe it can — its recoverable damages under a promissory estoppel theory would be limited to actual out-of-pocket reliance costs, not the full measure of expectation damages. See Loranger, 376 Mass. at 764. Vantage's actual reliance expenditures in developing the tri-state market — hiring additional sales representatives, establishing logistics arrangements, conducting customer outreach — are likely a fraction of the $35 million figure cited in the HSP letter. The $35 million figure almost certainly includes speculative projections of lost future profits, which are not recoverable under a reliance-based estoppel theory.
Assessment: Moderate nuisance value but low ultimate risk. The conditional and aspirational language of the Kapoor Email fundamentally undermines the "clear and unambiguous promise" element, and the integration and written-amendment clauses present additional doctrinal barriers. The primary risk associated with this claim is not its merits but the cost and distraction of defending against it through discovery and motion practice.
C. Overall Assessment of Vantage's Position
Taking the HSP letter as a whole, we assess Vantage's position as primarily a negotiating posture designed to achieve two objectives: (1) preserve its tri-state revenue stream (approximately $6.4 million over six months, and presumably growing), and (2) deter Penterra from finalizing the Meridian arrangement by raising the specter of protracted and expensive litigation.
The $35 million counterclaim figure appears inflated and unsupported. The HSP letter provides no breakdown, no methodology, and no factual basis for the number. It is, in our assessment, a figure designed for maximum psychological impact — a common tactic in pre-litigation demand letters. We should not allow it to distort our analysis of the actual risk, which we assess as follows:
• Breach of contract counterclaim: Low risk; depends entirely on the territory-interpretation question, which the plain language of Exhibit A resolves in Penterra's favor.
• Breach of implied covenant counterclaim: Low risk; the covenant cannot expand Vantage's contractual rights beyond the six New England states.
• Promissory estoppel counterclaim: Low-to-moderate nuisance value; the Kapoor Email lacks the clarity and specificity required to establish an enforceable promise, and the integrated nature of the Agreement presents an additional bar.
A critical strategic observation: Vantage's economic dependency on the Penterra relationship is a powerful settlement lever. Approximately 45.3% of Vantage's total revenue — roughly $67 million — is derived from Penterra products. Vantage cannot afford to jeopardize its New England exclusivity, which remains commercially valuable and unchallenged. If Penterra files suit and the litigation proceeds, Vantage will face the prospect of a judicial ruling that not only forecloses the tri-state area but also poisons the broader commercial relationship. This dynamic should give Vantage strong incentive to negotiate a reasonable resolution — but only after Penterra demonstrates that it is prepared to litigate.
V. Strategic Considerations
A. Risks and Vulnerabilities
While Penterra holds a strong contractual position, litigation outcomes are never certain, and we identify the following risks and vulnerabilities that warrant careful management:
Timing of objection. As noted above, the approximately six-month gap between Vantage's commencement of tri-state shipments (on or about September 14, 2020) and the cease-and-desist letter (March 8, 2021) is Penterra's most significant factual vulnerability. Vantage will argue that this delay constitutes knowing acquiescence and, when combined with the Kapoor Email, evidences a pattern of implicit consent to the territorial expansion.
Mitigation: The written-amendment clause (Section 13.1) and integration clause (Section 14.8) provide a strong contractual shield against waiver and acquiescence arguments. Under Massachusetts law, a waiver of contractual rights generally must be "clear and unmistakable" and cannot be inferred from mere silence or delay, particularly where the contract requires written amendments. Beacon Hill Civic Ass'n v. Ristorante Toscano, Inc., 422 Mass. 318, 322 (1996). Nevertheless, we must develop the factual record on the timing of Penterra's awareness and the reasons for the delay. Key questions to address: When did Rachel Mendez first identify the out-of-territory shipments in the distribution data? When was Steven Kapoor informed? When was Jennifer Chao consulted? Were there any internal discussions about addressing the matter through informal channels before escalating to a formal legal demand? A documented timeline showing that Penterra acted within a reasonable period after concluding its internal review will help rebut the acquiescence argument.
The Kapoor Email. While legally insufficient as consent or amendment, the Kapoor Email is a colorable piece of evidence that may create a factual dispute. The email demonstrates that at least one senior Penterra executive contemplated the possibility of tri-state expansion and communicated that contemplation to Vantage. Even if the court ultimately agrees that the email does not constitute consent, the very existence of the email gives Vantage's lawyers something concrete to argue about, which may complicate efforts to obtain summary judgment. Careful framing of the email — emphasizing its conditional language, its failure to satisfy the formal requirements of Sections 2.3 and 13.1, and the absence of any follow-up — will be essential.
Vantage's purchase growth. Vantage's consistently strong performance under the EDA — exceeding the $9.5 million annual minimum by substantial margins in every year — creates a sympathetic narrative. Vantage was a loyal, high-performing distributor that invested heavily in building the Penterra brand in New England. Vantage's counsel will argue that the parties' commercial relationship was a dynamic, evolving partnership, not a static contract limited to its four corners. While this narrative is legally irrelevant to the territorial question (purchase growth in New England does not authorize distribution in New York), it has the potential to influence judicial perception, particularly at the trial-court level. We should be prepared to acknowledge Vantage's strong performance while reframing it as evidence that the existing contractual arrangement was working well for both parties — not as evidence that the arrangement was somehow deficient or incomplete.
Late 2019 New York shipments. The HSP letter references Penterra's "failure to object to Vantage's shipments to New York beginning in late 2019." If true, this would mean that Vantage's unauthorized New York distribution began approximately ten months before the September 14, 2020 date reflected in Penterra's records, and approximately fifteen months before the cease-and-desist letter. This would significantly extend the timeline of alleged acquiescence and strengthen Vantage's course-of-dealing argument. We must investigate this claim immediately and determine: (a) whether there were, in fact, New York shipments in late 2019; (b) the volume and scope of any such shipments; (c) whether Penterra was aware of them; and (d) whether any Penterra personnel addressed or discussed them at the time.
B. Litigation Venue and Forum
Section 14.5 of the EDA provides for the exclusive jurisdiction of state or federal courts located in the Commonwealth of Massachusetts. This forum-selection clause is enforceable and should be invoked by Penterra to ensure that the dispute is litigated in a favorable and convenient forum.
We recommend filing the Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County. The Business Litigation Session ("BLS") is a specialized docket within the Massachusetts Superior Court that handles complex commercial disputes. The BLS judges — currently including Justices Salinger, Ricciuti, and others — are experienced in contract interpretation, commercial litigation, and summary-judgment practice. The BLS offers efficient case management, including expedited scheduling conferences, early attention to dispositive motions, and limited tolerance for discovery abuse. These attributes make the BLS an attractive forum for Penterra, whose strategy is premised on obtaining summary judgment based on the plain language of the EDA.
Filing a declaratory-judgment action under G.L. c. 231A allows Penterra to control the timing and framing of the dispute. The actual controversy is ripe: Vantage is currently engaging in unauthorized tri-state distribution, Penterra has demanded cessation, Vantage has refused, and Vantage has threatened a $35 million counterclaim. There is no requirement that Penterra wait for Vantage to file suit first. By filing proactively, Penterra seizes the initiative, frames the narrative (as a straightforward contract-interpretation case), and selects the forum.
C. Impact on the Meridian Arrangement
As noted above, Penterra executed a term sheet with Meridian National Distributors, Inc. on February 15, 2021, for the distribution of Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland. This arrangement represents a significant commercial opportunity, as it would establish dedicated distribution capabilities in the densely populated tri-state corridor and expand Penterra's geographic footprint in a high-demand market.
The Meridian deal has stalled since Vantage asserted its purported exclusive rights over the tri-state area. Thomas Welliver, Meridian's President, has indicated that Meridian is reluctant to invest in the infrastructure and staffing necessary to launch the tri-state distribution program until the legal cloud created by Vantage's claims is resolved. A favorable declaratory judgment — confirming that the Territory under the EDA is limited to the six New England states and that Penterra is free to appoint a different distributor in the tri-state area — would clear the path for Penterra to finalize and execute the Meridian distribution agreement.
Timing is a consideration. The EDA's original five-year term expires on June 30, 2022. While the declaratory-judgment question is independent of the EDA's term (Penterra has never granted Vantage tri-state rights, regardless of whether the EDA is in effect), a resolution before the term expires would simplify matters and avoid potential complications arising from the auto-renewal provisions. It would also allow Penterra to move forward with the Meridian deal on an expedited basis.
D. EDA Term Expiration
The EDA's initial five-year term expires on June 30, 2022. The Agreement provides for two successive one-year automatic renewal options, unless either party gives 180 days' prior written notice of non-renewal. For the first renewal period, this means that a notice of non-renewal must be sent by approximately January 1, 2022.
Penterra should consider whether to issue a notice of non-renewal as a belt-and-suspenders measure. Even if the litigation results in a favorable outcome on the territorial question, Penterra may wish to have the flexibility to renegotiate the terms of its distribution arrangement with Vantage (or to terminate the relationship entirely and pursue alternative distribution strategies for the New England market). Issuing a notice of non-renewal does not preclude Penterra from subsequently agreeing to a new distribution arrangement with Vantage on revised terms — it simply ensures that the current Agreement does not auto-renew and lock in the existing terms for an additional year.
We note that the decision to issue or withhold a non-renewal notice has strategic implications for both the litigation and the broader commercial relationship. On one hand, issuing a non-renewal notice could signal to Vantage that the entire relationship is at risk, which may increase Vantage's incentive to settle the tri-state dispute. On the other hand, it could harden Vantage's litigation posture by eliminating its incentive to preserve the relationship. We recommend preparing a separate client advisory on this topic, addressing the relevant commercial, legal, and strategic considerations in detail, with a recommended course of action by no later than November 2021 to allow adequate time for decision-making before the January 1, 2022 deadline.
VI. Recommended Litigation Strategy
A. Immediate Steps
Based on the foregoing analysis, we recommend the following immediate actions:
1. File a Complaint for Declaratory Judgment. Penterra should file a Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County, pursuant to G.L. c. 231A. The complaint should seek a declaration that: (a) the Territory under the EDA is limited to the six New England states defined in Exhibit A (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont); (b) the January 12, 2018 Kapoor Email does not constitute "prior written consent" under Section 2.3 of the EDA; (c) no amendment or modification of Exhibit A has occurred; and (d) Vantage's distribution of Oncalaris® in New York, New Jersey, and Pennsylvania constitutes a breach of Section 2.3 of the EDA. Target filing date: on or about April 12, 2021.
2. Issue a litigation hold notice. Penterra should issue a litigation hold notice to all personnel with potentially relevant knowledge or documents. Key custodians include: Dr. Marcus Lindholm (CEO), Jennifer Chao (General Counsel), Steven Kapoor (VP, Commercial Operations), Rachel Mendez (Director of Distribution & Logistics), and any other personnel involved in the Vantage relationship, the Kapoor Email exchange, or the monitoring of tri-state distribution activity. The hold notice should cover all documents and electronically stored information, including emails, text messages, instant messages, memoranda, reports, and any other records relating to the Vantage distribution relationship, the tri-state market, or the Meridian arrangement.
3. Preserve and collect key documents. The following documents should be immediately preserved and collected for litigation:
(a) The January 12, 2018 Kapoor Email and the complete surrounding email chain or thread, including any attachments, forwards, or replies;
(b) All communications between Penterra and Vantage personnel regarding the Territory, potential territorial expansion, tri-state distribution, and the Meridian arrangement;
(c) The EDA and all exhibits, schedules, and amendments thereto (we are not aware of any formal amendments, but this should be confirmed);
(d) The Meridian term sheet dated February 15, 2021;
(e) All internal Penterra communications (emails, memoranda, meeting notes, Meridian Solutions or Teams messages) referencing Vantage's tri-state activity, the Kapoor Email, or the territorial dispute; and
(f) Distribution reports and shipping data showing Vantage's product shipments by state and by date.
B. Anticipated Procedural Path
We anticipate the following procedural trajectory once the complaint is filed:
Answer and counterclaims. We anticipate that Vantage, through HSP, will file an Answer denying the material allegations of the complaint and asserting counterclaims for breach of contract, breach of the implied covenant of good faith and fair dealing, and promissory estoppel. The $35 million figure will almost certainly appear in the counterclaims, likely styled as a demand for compensatory damages, consequential damages, and such other relief as the court deems just and proper. We should be prepared to file a motion to dismiss or motion for judgment on the pleadings directed at the counterclaims to the extent they fail to state viable claims, although we may prefer to address them at summary judgment for strategic reasons.
Focused fact discovery. We recommend pursuing a focused discovery plan targeting the following subject areas:
(a) Vantage's understanding of the Territory at the time of execution. What did Donald Farnham and other Vantage personnel understand the Territory to include when they signed the EDA in July 2017? Did Vantage negotiate for tri-state inclusion and fail to obtain it? Were there earlier drafts of Exhibit A that reflected a different territorial definition?
(b) The circumstances surrounding the Kapoor Email. What prompted the email? Was there a meeting or phone call on January 11, 2018, as the email's reference to "good catching up yesterday" suggests? What was discussed? Did Farnham respond to the email, and if so, what did he say? Were there any subsequent communications about tri-state expansion between Kapoor and Farnham (or other Penterra and Vantage personnel)?
(c) The timing and extent of Vantage's tri-state activities. When precisely did Vantage begin shipping to New York? To New Jersey? To Pennsylvania? Were there shipments prior to September 14, 2020 (as the HSP letter suggests with respect to New York in late 2019)? What was the volume, frequency, and geographic reach of these shipments? What investments did Vantage make in tri-state infrastructure?
(d) Penterra's knowledge of and response to tri-state shipments. When did each relevant Penterra employee first become aware of Vantage's out-of-territory activity? What was the internal response? Were there any discussions about addressing the issue before the cease-and-desist letter? Why was the letter not sent sooner?
(e) Vantage's damages calculation. How was the $35 million figure derived? What are its components? What assumptions underlie the lost-profits projections? What actual out-of-pocket expenditures did Vantage make in reliance on the alleged promise of tri-state expansion?
Target depositions. On